Carla Abdelnour

The need for revised outcome measures in DLB trials 0:57
The need for revised outcome measures in DLB trials
Carla Abdelnour • 17 Jul 2023
Biomarkers in DLB trials 1:57
Biomarkers in DLB trials
Carla Abdelnour • 17 Jul 2023
Plasma p-tau181 to identify Alzheimer’s disease-related co-pathology in DLB 1:57
Plasma p-tau181 to identify Alzheimer’s disease-related co-pathology in DLB
Carla Abdelnour • 17 Jul 2023
A review of current clinical trials in dementia with Lewy bodies 3:06
A review of current clinical trials in dementia with Lewy bodies
Carla Abdelnour • 17 Jul 2023
Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease 2:41
Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease
Carla Abdelnour • 29 Nov 2022
Implementing novel clinical trial designs for dementia with Lewy bodies 3:07
Implementing novel clinical trial designs for dementia with Lewy bodies
Carla Abdelnour • 29 Nov 2022
Challenges in designing clinical trials for dementia with Lewy bodies 1:33
Challenges in designing clinical trials for dementia with Lewy bodies
Carla Abdelnour • 29 Nov 2022
The content of VJDementia is intended for healthcare professionals